

# 2021 | CHANGES TO CPT CODING



The American Medical Association publishes the *Current Procedural Terminology* (CPT) coding manual on an annual basis. For 2021, the pathology and laboratory section of the CPT manual includes 37 new Category I CPTs, nine CPT description revisions and one CPT deletion; as well as 81 new Proprietary Laboratory Analyses (PLA) codes, three PLA code description revisions, and seven deleted PLA codes. Esoterix will begin submitting the 2021 CPT codes on **January 1, 2021**, unless other guidance is received.

The 2021 CPT code changes presented below, which affect two

published tests on the Test Menu at [www.esoterix.com](http://www.esoterix.com), are intended as general guidelines and are based on the AMA's 2021 CPT code manual. You should confirm with the applicable payer that their use is appropriate in each case as the billing party is responsible for its CPT coding. The list below does not include any custom profiles created for individual clients.

We hope that this information will be beneficial to your office staff. Please contact your local Esoterix service representative if you have questions. Thank you for selecting Esoterix as your laboratory services provider.

| Test Name                          | Test No. | 2020 CPT     | 2021 CPT     |
|------------------------------------|----------|--------------|--------------|
| Estradiol, Free                    | 500149   | 82670; 84999 | 82670; 82681 |
| Methotrexate Polyglutamates, Blood | 803960   | 80375        | 80204        |

**Please note:** This 2021 CPT update affects all profiles that contain the assays listed above.

The CPT codes listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payer that their use is appropriate in each case.